In prospective studies, there was little difference between FD and gastroparesis patients, particularly with respect to symptom severity and quality of life, clinical course with limited improvement over a 48-week follow-up, and gastric neuropathology with loss of ICCs and CD206+ macrophages. This evidence concerns the gene MRC1 and gastroparesis.